98%
921
2 minutes
20
Cancer is a major global health concern. Therefore, new treatment options are needed. The phytochemicals have different chemical structures. It also exhibits several other biological activities. Therefore, these compounds are promising anticancer agents. This review aims to identify and assess new candidates for anticancer therapy. Researchers have identified these compounds among the well-studied plant chemicals and their actions. Thus, these compounds can be used in anticancer therapies. The popularity of phytochemicals has grown. Currently, these are the subjects of extensive investigational studies. However, obstacles remain in its development and translation for clinical use. This is especially true for low bioavailability. These compounds also exhibit a wide range of activities, toxicities, and regulatory activities. These are necessary for the isolation and characterization of phytochemicals. This review discusses these challenges and the recent progress. Emphasis has been placed on integrating traditional knowledge of medicines with current biomedical advancements to augment the efficacy of phytoconstituents for cancer treatment. The review indicates new treatment frameworks with the synergy of traditional systems of medicine (e.g., Traditional Chinese Medicine [TCM] and Ayurveda) and new approaches today, such as nanotechnology and artificial intelligence-assisted drug discovery. This review also highlights the clinical efficacy of such phytoconstituents and addresses key developmental bottlenecks, such as bioavailability, regulatory barriers, and standardized methods of extraction. These include the extraction methods, delivery systems, and clinical findings. It focuses on the merging of modern and traditional medicine. The goal of this study was to maximize the potential of these phytochemicals. This will help to create successful cancer treatments. A thorough analysis was done using primary databases, namely PubMed, Scopus, Web of Science, and Google Scholar, for articles between 2020 and 2023. The relevant literature was searched using keywords such as phytochemicals, anticancer mechanisms, bioavailability, delivery systems, and clinical efficacy. The selected articles included peer-reviewed studies that compared the anticancer mechanisms of phytochemicals, challenges encountered in their development, new advances in extraction and delivery technologies, and clinical reports of their therapeutic efficacy. This approach allowed a wide synthesis of existing knowledge around phytochemicals as anticancer drugs. This review summarizes our knowledge of phytochemicals as potential anticancer agents. This finding fills a gap in the literature. This offers new insights into their roles in personalized cancer treatment. This explains the mechanisms of action and challenges in development. This places these compounds at the forefront of, and complements, cancer treatment. Considerable research is required to boost personalized oncology research. This leads to improved patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351433 | PMC |
http://dx.doi.org/10.1002/cbdv.202402479 | DOI Listing |
JMIR Res Protoc
September 2025
Department of Health Services Research & Administration, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.
View Article and Find Full Text PDFOncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFMultimed Man Cardiothorac Surg
September 2025
Institute of Chest Surgery, Medanta, Gurugram, India
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant inherited disorder caused by mutation in a tumour suppressor gene, FLCN, leading to skin tumours (fibrofolliculomas), renal tumours and pulmonary cysts. Lung involvement is predominantly observed in 70% of the cases of BHDS, manifesting in the form of recurrent primary spontaneous pneumothorax. This video tutorial showcases the surgical management of recurrent right primary spontaneous pneumothorax in a young adult with a history of multiple episodes of bilateral pneumothorax managed by surgical intervention previously.
View Article and Find Full Text PDFMultimed Man Cardiothorac Surg
September 2025
Department of Thoracic Surgery, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton, UK
Three-dimensional (3D) guided robotic-assisted thoracic surgery is increasingly recognized as the pioneering approach for the most complex of pulmonary resections, offering high-definition 3D visualization, enhanced instrument augmentation and tremor-free tissue articulation. Compared with open thoracotomy, the robotic platform is associated with reduced peri-operative morbidity, shorter hospital admissions and faster patient recovery. However, sublobar resections such as segmentectomies remain anatomically and technically demanding, particularly in the context of resecting multiple segments, as showcased in this right S1 and S2 segmentectomy.
View Article and Find Full Text PDFJ Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDF